首页> 外文期刊>Molecular genetics and metabolism >Pre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA)
【24h】

Pre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA)

机译:在甲基丙二酸血症(MMA)鼠模型中表达人甲基丙二酰-CoA突变酶的AAV8载体的临床前疗效和剂量

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We demonstrate that human methylmalonyl-CoA mutase (MUT), delivered using an AAV serotype 8 vector, rescues the lethal phenotype displayed by mice with MMA and provides long-term phenotypic correction. In addition to defining a lower limit of effective dosing, our studies establish that neither a species barrier to mitochondrial processing nor an apparent immune response to MUT limits the murine model as an experimental platform to test the efficacy of human gene therapy vectors for MMA.
机译:我们证明,使用AAV血清型8载体交付的人类甲基丙二酰辅酶A突变酶(MUT),可以挽救MMA小鼠显示的致死表型,并提供长期的表型校正。除了确定有效剂量的下限外,我们的研究还确定,线粒体加工的物种障碍和对MUT的明显免疫反应都不会限制鼠模型作为实验平台,以测试人类基因治疗载体对MMA的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号